Medical Advisory Board for RENCAREX®

WILEX’s Medical Advisory Board for RENCAREX® is composed of international experts in the fields of biology and medicine, particularly oncologists and urologists.

Arie Belldegrun, MD, FACS (Chairman of the Advisory Board)
Roy and Carol Doumani Chair in Urologic Oncology;
Professor of Urology; and Chief, Division of Urologic Oncology;
Department of Urology at the David Geffen School of Medicine at UCLA, Los Angeles, CA.

Michael B. Atkins, MD
Deputy Director Division of Hematology/Oncology, Beth Israel Deaconess Medical Center;
Leader of the Renal Cancer Program, Dana Farber-Harvard Cancer Center;
Professor of Medicine, Harvard Medical School, Boston, MA.

Michael L. Blute, MD
Chair of the Department of Urology, Mayo Clinic;
Anson L. Clark Professor of Urology, Mayo Clinic College of Medicine, Rochester, Minnesota.

John Michael Fitzpatrick, MCh, FRCSI, FC Urol (SA), FRCSGlas, FRCS
Professor and Chairman, Department of Surgery, Mater Misericordiae Hospital, Dublin and University College;
Consultant Urologist, Mater Misericordiae Hospital, Dublin, Ireland.

Adrian L. Harris, MD, PhD
Director of Cancer Research UK Medical Oncology Unit at the Churchill Hospital, University of Oxford;
Director of the Molecular Oncology Laboratories at the Weatherall Institute of Molecular Medicine;
Consultant Medical Oncologist and Professorial Fellow of St Hugh's College Oxford.

Hakan Mellstedt, MD, PhD
Chief Physician, Department of Oncology, Karolinska Hospital;
Professor of Oncologic Biotherapy at the Karolinska Institute;
Managing Director of Cancer Center Karolinska, Karolinska Institute, Stockholm, Sweden.

Jean-Jacques Patard, MD, PhD
Professor of Urology, Department of Urology, University of Rennes, France.

Nicholas Vogelzang, MD
Chair and Medical Director Developmental Therapeutics and Co-Chair GU Committee, US Oncology Research, Comprehensive Cancer Centers of NV, Las Vegas, USA

Medical Advisory Board for Small Molecules Kinase Inhibitors

Jose Baselga, M.D.
Chief of Medical Oncology, Associate Chief of the MGH Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, USA
Professor of Medicine, Harvard Medical School, Cambridge, Massachusetts, USA

Roger B. Cohen, M.D.
Professor of Medical Oncology, Director Phase I Clinical Trials Program, Co-Leader Developmental Therapeutics Program, Fox Chase Cancer Center Philadelphia, Pennsylvania, USA

Prof. Herbie Newell
Professor of Cancer Therapeutics at the Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Medical School, Newcastle upon Tyne, UK

Judith S. Sebolt-Leopold, Ph.D.
Research Associate Professor, Center for Molecular Imaging, University of Michigan, Department of Radiology, Ann Arbor, Michigan, USA

David B. Solit, M.D.
Elizabeth and Felix Rohatyn Chair, Memorial Sloan-Kettering Cancer Center, Department of Medicine, New York, New York, USA

Prof. Paul Workman PhD DSc FMedSci
Harrap Professor of Pharmacology & Therapeutics, Director of the Cancer Research UK Centre for Cancer Therapeutics , Cancer Research UK Life Fellow, Leader of the Signal Transduction and Molecular Pharmacology Team and Co-Team Leader of the Clinical Pharmacology and Trials Team, The Institute for Cancer Research (ICR), Sutton, UK